argenx SE (EBR:ARGX)
Belgium flag Belgium · Delayed Price · Currency is EUR
604.00
+1.40 (0.23%)
Aug 29, 2025, 5:35 PM CET
0.23%
Market Cap36.96B
Revenue (ttm)2.66B
Net Income (ttm)1.09B
Shares Out61.20M
EPS (ttm)15.96
PE Ratio37.84
Forward PE34.78
Dividendn/a
Ex-Dividend Daten/a
Volume93,983
Average Volume93,624
Open604.80
Previous Close602.60
Day's Range600.60 - 616.40
52-Week Range456.30 - 658.00
Beta0.00
RSI66.65
Earnings DateOct 30, 2025

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange Euronext Brussels
Ticker Symbol ARGX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

argenx to Present at Upcoming Investor Conferences

August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...

3 days ago - GlobeNewsWire

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded

Argenx saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.

5 days ago - Investor's Business Daily

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ: ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod...

5 days ago - Benzinga

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab)...

5 days ago - Benzinga

Argenx Tops Buy Point On Bullish Study, 850 Price Target

Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart.

6 days ago - Investor's Business Daily

Argenx Targets FDA Label Expansion After Vyvgart Trial Success

Argenx reported positive Phase 3 Vyvgart data in ... Full story available on Benzinga.com

6 days ago - Benzinga

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegati...

6 days ago - GlobeNewsWire

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...

12 days ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contac...

14 days ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...

15 days ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contac...

18 days ago - GlobeNewsWire

Monica Seles: Reveals Myasthenia Gravis Diagnosis; champion's battle against Autoimmune Disease

Tennis legend Monica Seles, a nine-time Grand Slam champion, reveals her three-year battle with myasthenia gravis (MG), a rare neuromuscular disease. At 51, Seles is speaking out to raise awareness, p...

18 days ago - The Times of India

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life

19 days ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...

20 days ago - PRNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contac...

22 days ago - GlobeNewsWire

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 10.06% on an annualized basis producing an average annual return of 23.85%. Currently, argenx has a market capitalization of...

23 days ago - Benzinga

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...

24 days ago - Seeking Alpha

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...

25 days ago - PRNewsWire

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

4 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

4 weeks ago - CNBC Television

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

argenx SE (NASDAQ:ARGX) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Masse...

4 weeks ago - Seeking Alpha

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Da...

4 weeks ago - PRNewsWire

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS foll...

4 weeks ago - GlobeNewsWire

argenx SE 1H 2025 Earnings Preview

4 weeks ago - Seeking Alpha